



Please type a plus-sign (+) inside this box



PTO/SB/83 (08-00)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR WITHDRAWAL AS ATTORNEY OR AGENT

Application Number	09/010,377
Filing Date	01/21/98
First Named Inventor	S.A. Rubin et al.
Group Art Unit	1644
Examiner Name	Phillip Gambel
Attorney Docket Number	015270-004300US

H27

To: Assistant Commissioner for Patents
Washington, DC 20231

I hereby apply to withdraw as attorney or agent for the attached identified applications.

The reasons for this request are: request of assignee
see Exhibit A

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

- ☐ The correspondence address is NOT affected by this withdrawal.
- ☒ Change the correspondence address and direct all future correspondence to:

CORRESPONDENCE ADDRESS

☐ Customer Number
OR

Place Customer Number
Bar Code Label here

☒ Firm or
Individual Name

Teresa Stanek Rea, Esq.

Address

Burns Doane Swecker & Mathis, LLP

Address

1737 King Street, Suite 500

City

Alexandria

State

VA

ZIP

22314

Country

U.S.A.

Telephone

703-836-6620

Fax

703-836-2021

This request is enclosed in triplicate.

Name

Joe Liebeschuetz, Reg. No. 37,505

Signature

Joe Liebeschuetz

Date

6/11/2002

APPROVED

William J. Hefley
5/21/02 7016000
6/28/02

NOTE: Withdrawal is effective when approved rather than when received
Unless there are at least 30 days between approval of withdrawal and the expiration date of a time
period for response or possible extension period, the request to withdraw is normally disapproved.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3228603 v1PA 3228603 v1

3/06/02 14:40 FAX

élan



COPY

800 Gateway Boulevard
South San Francisco, CA 94080
T (650) 877 0900
F (650) 877 8370
Direct Legal T: (650) 794-4375
Direct Legal F: (650) 553 7165

FAX

To Andrew Serafini, Esq.
Townsend Townsend & Crew

Fax 650-326-2422

From Joe Liebeschuetz, Esq.
Townsend Townsend & Crew
Dianna DeVore
Associate Director, Patents
Elan Pharmaceuticals Inc.

Date May 8, 2002

Copy

Page Page 1 of 5

Subject **Transfer of Prosecution Responsibility**

Please see attached.

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

If transmission was faulty, contact: FAYE KNOWLES @ (650) 866-2774

Elan Pharmaceuticals, Inc.
a member of the Elan Group

Warning: This communication is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return this original message to us at the above address via the mail service. Thank you.



800 Gateway Boulevard
South San Francisco, CA 94080
T (650) 877 0900 F (650) 877 8370

May 8, 2002

Andrew Serafini, Esq.
Townsend & Townsend & Crew
379 Lytton Avenue
Palo Alto, CA 94301-1431

Sent Via Facsimile to: 650-326-2422
Original sent via U.S. Mail

RECEIVED
JUN 21 2002
TECH CENTER 1600/2900

Re: Transfer of Prosecution Responsibility

For: BLOOD BRAIN BARRIER MODEL
Our Reference No.: 101 Series
Your Reference No.: 15270-0032 Series

For: HUMANIZED ANTIBODIES AGAINST LEUKOCYTE
ADHESION MOLECULE VLA-4
Our Reference No.: 120 Series
Your References No. 15270-0014

For: TREATMENT OF VIRAL ENCEPHALITIS BY AGENTS
BLOCKING ALPHA-4 INTEGRIN FUNCTION
Our Reference No.: 00188 US Case
Your Reference No.: 015270-004300US

Dear Andrew:

We have decided to transfer in their entirety all cases as listed on attached Exhibit A to Burns, Doane Swecker & Mathis, LLP. Accordingly, please transfer the original files to the following address:

Teresa Stanek Rea, Esq..
Burns Doane Swecker & Mathis, LLP
Suite 500
1737 King Street
Alexandria, VA 22314-2727

Please include a list of all outstanding items, and both an action and regular docket for all cases listed in Exhibit A.

BIOPHARMACEUTICALS

Elan Pharmaceuticals, Inc.
a member of the Elan Group

Andrew Serafini, Esq.
May 8, 2002
Page 2

We have been pleased with your firm and hope to continue our relationship for the remaining Elan cases currently handled by Townsend.

Please acknowledge receipt of these files by kindly returning one copy of this letter to us at your earliest convenience.

Should you have any questions, feel free to contact me at (650) 794-4375.

Very truly yours,



Dianna DeVore
Associate Director, Patents

Enclosures

DLD/fdk

cc: Joe Liebeschutz, Esq. (w/ enclosures)
Teresa Stanek Rea, Esq. (w/ enclosures)
Jean Duvall, Esq. (w/o enclosures)

RECEIPT IS ACKNOWLEDGED OF THE ABOVE-IDENTIFIED FILES:

Date: _____

By: _____

Andrew Serafini, Esq.
May 8, 2002
Page 3

EXHIBIT A

Elan Reference No.

Patent/Serial No.

Townsend Reference No.

Your Reference No.
15270-0032
Including:

101-US-CIP1
101-CA-CIP1
101-JP-CIP1
101-US-CON2
101-US-CON3

5,260,210
2,066,73 8
2-513049
08/402,962
6,033,665

15270-003210US
15270-003210CA
15270-003210JP ✓
15270-003213US
15270-003215US

Elan Reference No.

Patent/Serial No.

Townsend Reference No.

Your Reference No.
15270-0014
Including:

120-AU-NEW
120-CA-NEW
120-CA-CIP1
120-CN-NEW
120-EPO-CIP1
120-EPO-NEW
120-FI-NEW
120-HU-NEW
120-JP-CIP1
120-JP-NEW
120-KR-NEW
120-MX-NEW
120-NO-NEW
120-NZ-NEW
120-PL-NEW
120-US-CIP1

703152
2,182,013
2,237,808
95191354.9
96943512.2
95908741.2
962958
P9602019
9-519938
7-519770
96-703987
198845
96.3097
279730
P315634
09/155,739

15270-001410AU
15270-001410CA
15270-001430CA
15270-001410CN
15270-001430EP
15270-001410EP
15270-001410FI
15270-001410HU
15270-001430JP
15270-001410JP
15270-001410KR
15270-001410MX
15270-001410NO
15270-001410NZ
15270-001410PL
15270-001430US

03/08/02 14:40 FAX
Andrew Serafini, Esq.
May 8, 2002
Page 4

Elan Reference No.

Patent/Serial No.

Townsend Reference No.

Your Reference No.
15270-0014
Including:

120-US-CIP2
120-PCT-NEW
120-PCT-CIP1

5,840,299
PCT/US95/01219
PCT/US96/18807

15270-001420US
15270-14-1PC
15270-1430PC

Elan Reference No.

Patent/Serial No.

Townsend Reference No.

Your Reference No.
15270-0043
Including:

188-US-NEW

09/010,377

15270-004300US